To start your customized experience click the start button
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Meeri Kim
More personalized approaches are being developed to treat patients with metastatic disease.
Kelly Irvin
Scoring the big NED often leads to that "Terminator" voice whispering in your ear.
Jason M. Broderick
Yervoy (ipilimumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of pediatric patients who are 12 years old or younger and have unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.
Ariela Katz
A study pairs an IDO inhibitor with PD-1 checkpoint blockade.
Jason M. Broderick
Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a response in some patients with melanoma brain metastases, according to a recent study presented at ASCO. 
Lauren M. Green
Patients with in immunotherapy-naïve and pretreated patients with advanced melanoma saw a 50 percent overall response rate (ORR) when adding a formulation of the Coxsackievirus A21 (CVA21; CAVATAK®) to Yervoy (ipilimumab) – a combination which was well-tolerated.
Diana M. Martin
A plan for remembering your loved one when times get tough.
Jason M. Broderick
The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
Jason Broderick
The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
Jason Harris
Immunotherapy showed improved survival benefits for stage 3 and 4 melanoma, but it came at a price of greater toxicity, according to a randomized, double-blind phase 3 study that compared 10 mg/kg Yervoy (ipilimumab) or a lower dose of the anti-CTLA-4 anticlonal antibody.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable